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Prospective cohort studies (PCS) observe one or more groups of exposure or outcome (e.g. sicker patients leave the study before they
subjects longitudinally over time to determine the incidence of a
speciﬁc outcome after different exposures to a particular factor (for
instance drugs, interventions or risk factors). Thereby, nature and
strength of a potential relationship between exposure and outcome
can be assessed: For example, how many subjects with asymptom-
atic peripheral arterial disease will develop intermittent claudication
and what risk factors are associated? Or does anticoagulant therapy
affect the incidence of endoleaks after endovascular aortic repair?
Several important aspects need to be considered when assessing
observational studies: First, PCS are being used to investigate causes of
diseases, particularly if the more rigorous methodology of randomized
controlled trial (RCT) is unethical or not feasible. Representing the next
best available scientiﬁc method, PCSs are usually designed to test
hypotheses about prognosis or etiology. However, PCS are susceptible
to confounding! Therefore, they are intrinsically inappropriate to
prove efﬁcacy of treatment interventions or validity of diagnostic
tests. In observational studies, exposures are never randomly assigned
increasing the risk that, in reality, unmeasured variables other than the
exposure (i.e. “confounders”) explain the outcome difference and not
the investigated exposure. In this context, confounding means
“confusion of effects”. In above example, unrecognized smoking or
diabetic status could confound for instance the suspected effects of
carrying matches or obesity on developing intermittent claudication.
Similarly, reverse causation may theoretically occur without notice -
for instance if patients at higher risk of the disease receive a speciﬁc
treatment earlier. In PCS, outcomes occur normally after enrolment
suggesting the “direction” of a potentially causal relationship. None-
theless, investigators always need to scrutinize the temporal sequence
between exposure and outcome. In addition, they must control for
suspected confounders using appropriate statistical methods. Strati-
ﬁcation (sub-grouping) and multivariate regression models are the
two most commonly used statistical techniques; both have their own
assumptions, advantages and limitations, but none of them can
eliminate bias related to unmeasured or unknown confounders.
Generally, PCS are apt in generating hypotheses and suggesting cau-
sality but can never prove it.
Second, a major objective of PCS is to establish incidence rates for
speciﬁc outcomes or diseases. The proportions of subjects devel-
oping the outcome are then compared between the exposure groups
to provide a “risk ratio” (i.e., relative risk, RR) indicating strength and
direction of the association between exposure and outcome. A RR of
1.0 reﬂects absence of any association since exposed subjects are
neither more nor less likely to develop the outcome than unexposed
subjects. A RR greater than 1.0 implies a positive correlation be-
tween exposure and the risk of developing the disease, whereas a RR
of less than 1.0 implies a protective effect of the exposure regarding
the disease. However, losing subjects during follow-up is a main
concern in longitudinal research leading to missing (and probably
selective) information. Differential loss of information may introduce
“length-time” bias and mislead risk calculations in PCS: if subjects
drop out from the study for reasons that are related to their1078-5884/ 2015 European Society for Vascular Surgery. Published by
Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.ejvs.2015.09.021die), then study ﬁndings are likely biased. The loss of only a few cases
developing the outcome can seriously affect the numerator and
hence distort the result of incidence analyses. The rarer the outcome
the more signiﬁcant is this effect.1 Therefore, loss to follow-up
should be anticipated and sample sizes increased accordingly. For
example, if it is likely that 20% of participants will be lost, the power
calculated sample should be increased by a factor of 1/(1e0.20), or
by 25 percent.2 Nonetheless, adapted sample sizes cannot fully
compensate for missing follow-up data. Investigators need to give
every effort to collect complete follow-up information and should
declare the aggregate proportion of missed follow-up.
Third, the main advantage of PCS over retrospective cohort and
caseecontrol studies is that baseline exposure status is correctly
assessed, not only recalled. This reduces the risk of selection bias,
because it is much less likely in a PCS that an outcome would in-
ﬂuence the individual classiﬁcation of an exposure or affect study
inclusion post hoc. For example, presence of an endoleak unlikely
affects classiﬁcation of anticoagulant therapy if the latter was
determined upfront. This, in contrast, means that PCS data analysis
must await sufﬁcient follow-up time after a study started. Therefore
PCS may be very expensive and time consuming and are not suitable
for rare diseases or diseases with a long latency.
Fourth, all of the above can only be achieved if selection and size of
the target population and choice and timing of the variables to be
measured are determined in advance. Therefore, PCS rely on carefully
designed case record forms (CRF, either on paper or electronic). How-
ever, even in carefully designed PCS, external validity may be insufﬁ-
cient, if the study population is not representative of the patients of
interest (selection bias).3 Furthermore, failure to collect CRF data in real
time (leading to “retrospective recording”) is another reason for
concern, particularly, if multicentre or large samples are involved. To
reduce this risk, CRF should be clear and unambiguous, easy to complete
and in a format that suits all users and simpliﬁes data analysis.
And ﬁnally, PCS should be reported according to the STROBE
guidelines. Reading these guidelines before starting a study will
improve the study design and increase the probability of successful
study completion.
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